Journal List > J Rheum Dis > v.20(6) > 1064078

TOOLS
Choi, Lee, Song, Kim, Jang, Jung, Choi, Park, Park, Lee, Lee, Baek, and Kim: A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis
Case Report

J Rheum Dis 2013;20(6):361-363.

Published online: 31 December 2013

DOI: https://doi.org/10.4078/jrd.2013.20.6.361

A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis

Sang-A Choi1, Seung-Geun Lee1, Sang-Heon Song1, Ji-Min Kim1, Hye-Yoon Jang1, Woo-Jin Jung1, Jong-Hyun Choi1, Young-Eun Park2, Seong-Hu Park3, Joung-Wook Lee4, Jun-Hee Lee5, Seung-Hoon Baek5, Geun-Tae Kim6

1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea

2Malgeunsem Hospital, Changwon, Korea

3Young-do Hospita, Busan, Korea

4Busan St. Mary's Medical Center, Ilsin Christian Hospital, Busan, Korea

5Division of Rheumatology, Department of Internal Medicine, Ilsin Christian Hospital, Busan, Korea

6Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

Corresponding to : Seung-Hoon Baek, Division of Rheumatology, Department of Internal Medicine, Ilsin Christian Hospital, Geumgokdaero 264-1, Buk-gu, Busan 616-854, Korea. E-mail : drbaek@pusan.ac.kr

Received 17 October 2012       Accepted 7 November 2012

Copyright © 2013 The Korean College of Rheumatology

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Treatments for patient with ankylosing spondylitis (AS) in-clude nonsteroidal antiinflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNFα) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFα agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFα agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.

Keywords: Ankylosing spondylitis, End-stage renal disease, Peritoneal dialysis, Tumor necrosis factor-alpha

References

1. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998; 17:524–30.
crossref
2. van der Heijde D, Sieper J, Maksymowych WP, Douga-dos M, Burgos-Vargas R, Landewe R, et al. Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; 70:905–8.
crossref
3. Lange U, Stapfer G, Ditting T, Geiger H, Teichmann J, Müller-Ladner U, et al. Pathologic alterations of the heart and the kidney in patients with ankylosing spondylitis. Eur J Med Res. 2007; 12:573–81.
4. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011; 70:896–904.
crossref
5. Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2007; 13:629–38.
6. Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005; 57:1407–13.
crossref
7. Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006; 45:357–9.
crossref
8. Sugioka Y, Inui K, Koike T. Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol. 2008; 18:293–5.
crossref
9. Saougou I, Papagoras C, Markatseli TE, Voulgari PV, Drosos AA. A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review. Clin Rheumatol. 2010; 29:1455–9.
crossref
10. Shimojima Y, Matsuda M, Ishii W, Ikeda S. Adalimumab monotherapy in a patient with psoriatic arthritis associated with chronic renal failure on hemodialysis: a case report and literature review. Clin Med Insights Case Rep. 2012; 5:13–7.
crossref
11. Kobak S. Efficacy and safety of adalimumab in a patient with ankylosing spondylitis on peritoneal dialysis. Rheumatol Int. 2012; 32:1785–7.
crossref

Table 1.
Clinical and laboratory findings in our patient with ankylosing spondylitis receiving peritoneal dialysis during etanercept treatment
  Baseline 3 month 9 month
BASDAI 7.7 4.6 1.2
BASFI 7.7 4.2 5.5
BASMI 5.6 3.8 3.6
ASDAS-CRP 4.55 4.03 1.8
ASDAS-ESR 5.85 4.57 2.96
CRP, mg/dL 19.4 9.1 2.3
ESR, mm/hr 120 95 59
BUN, mg/dL 71.2 66.5 74.8
Serum creatinine, mg/dL 11.8 12.2 12.1

BASDAI: bath ankylosing spondylitis disease activity index, BASFI: bath ankylosing spondylitis functional index, BASMI: bath ankylosing spondylitis metrology index, ASDAS: ankylosing spondylitis disease activity score, CRP: c-reactive protein, ESR: erythrocyte sedimentation rate, BUN: blood urea nitrogen.

TOOLS
Similar articles